When did ResMed report Q2 2025 earnings?

ResMed (RMD) reported Q2 2025 earnings on January 30, 2025 after market close.

What were ResMed's Q2 2025 revenue and EPS?

ResMed reported revenue of $1.3B and diluted EPS of $2.43 for Q2 2025.

Did ResMed beat estimates in Q2 2025?

Revenue beat the consensus estimate of $1.3B by $15.4M. EPS beat the consensus estimate of $2.32 by $0.11.

Where can I find ResMed's Q2 2025 SEC filings?

You can read the 10-Q periodic report (0000943819-25-000004) directly on SEC EDGAR. The filing index links above go to sec.gov.

ResMed RMD Q2 2025 earnings

Reported January 30, 2025 · After market close

Revenue$1.3BBeat by $15.4M Diluted EPS$2.43Beat by $0.11

Revenue estimate$1.3B

EPS estimate$2.32

Next report

Aug 6, 2026 (In 3 weeks)

Revenue estimate$1.5B

EPS estimate$2.90

Financials

Q2 2025

Income statement

See full

Revenue$1.3B+10.3%

Gross profit$751.3M+16.1%

Operating income$417.2M+51.7%

Net income$344.6M+65.0%

EPS (diluted)$2.34+64.8%

Balance sheet

See full

Cash & equivalents$521.9M+148%

Total debt$849.6M-39.4%

Total equity$5.3B+17.2%

Total assets$7.1B+3.4%

Cash flow

See full

Operating cash flow$308.6M+13.1%

CapEx$20.6M-11.6%

Free cash flow$288.0M+15.4%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$33.57B+32.6%

Enterprise value$33.9B+27.9%

P/E26.9×-1.5×

P/S6.8×+1.2×

Profitability

See full

Gross margin58.4%+3.3pp

Operating margin31.7%+6.4pp

Net margin25.3%+5.6pp

FCF margin28.2%+6.9pp

Returns & leverage

See full

Return on equity25.7%+4.0pp

Debt / equity0.2×-0.2×

Current ratio3.3×+0.2×

Segments

By product

See full

Devices$1.3B+10.4%

Sleep And Breathing Health$1.1B+10.6%

Masks and other$912.6M+10.8%

Residential Care Software$156.5M+8.0%

By geography

See full

Global revenue$1.3B+10.3%

U.S., Canada and Latin America$748.9M+11.9%

Combined Europe, Asia and other markets$376.6M+8.1%

By segment

See full

Sleep and Breathing Health$1.1B+10.6%

Residential Care Software$156.5M+8.0%

Versus estimates

Revenue

Q3 2026$1.4BBeat by $11.5M Q2 2026$1.4BBeat by $22.3M Q1 2026$1.3BBeat by $2.3M Q4 2025$1.3BIn line Q3 2025$1.3BBeat by $3.6M

Q2 2025$1.3BBeat by $15.4M

Diluted EPS

Q3 2026$2.86Beat by $0.07 Q2 2026$2.81Beat by $0.07 Q1 2026$2.55Beat by $0.04 Q4 2025$2.55In line Q3 2025$2.37Miss by $0.01

Q2 2025$2.43Beat by $0.11

Ask the moment ResMed reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did ResMed report Q2 2025 earnings?: ResMed (RMD) reported Q2 2025 earnings on January 30, 2025 after market close.
What were ResMed's Q2 2025 revenue and EPS?: ResMed reported revenue of $1.3B and diluted EPS of $2.43 for Q2 2025.
Did ResMed beat estimates in Q2 2025?: Revenue beat the consensus estimate of $1.3B by $15.4M. EPS beat the consensus estimate of $2.32 by $0.11.
Where can I find ResMed's Q2 2025 SEC filings?: You can read the 10-Q periodic report (0000943819-25-000004) directly on SEC EDGAR. The filing index links above go to sec.gov.